Compare · ABT vs SDEV
ABT vs SDEV
Side-by-side comparison of Abbott Laboratories (ABT) and Stablecoin Development Corporation (SDEV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and SDEV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $176.55B, about 4063.5x SDEV ($43.4M).
- Over the past year, ABT is down 23.1% and SDEV is down 92.0% - ABT leads by 68.9 points.
- ABT has been more active in the news (9 items in the past 4 weeks vs 2 for SDEV).
- ABT has more recent analyst coverage (25 ratings vs 0 for SDEV).
- Company
- Abbott Laboratories
- Stablecoin Development Corporation
- Price
- $102.03-1.02%
- $0.87-0.68%
- Market cap
- $176.55B
- $43.4M
- 1M return
- -8.30%
- -15.15%
- 1Y return
- -23.15%
- -92.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- News (4w)
- 9
- 2
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- First Canadian Commercial Use of Abbott's Volt™ Pulsed Field Ablation System Advances Minimally Invasive Atrial Fibrillation Care
- Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall
- Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
- VICE PRESIDENT AND CONTROLLER Mccoy John A. Jr. covered exercise/tax liability with 52 units of Common shares without par value and sold $2,958 worth of Common shares without par value (27 units at $109.54), decreasing direct ownership by 0.32% to 24,549 units (SEC Form 4)
- EVP AND CFO Boudreau Philip P covered exercise/tax liability with 388 units of Common shares without par value, decreasing direct ownership by 0.55% to 70,784 units (SEC Form 4)
- Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
- CHAIRMAN AND CEO Ford Robert B exercised 398,832 units of Common shares without par value at a strike of $54.02 and sold $46,204,798 worth of Common shares without par value (398,832 units at $115.85) (SEC Form 4)
- Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Latest SDEV
- SEC Form 3 filed by new insider Rios David Garcia
- Stablecoin Development Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits
- SEC Form S-3 filed by Stablecoin Development Corporation
- Stablecoin Development Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results
- SEC Form 10-Q filed by Stablecoin Development Corporation
- Amendment: SEC Form SCHEDULE 13D/A filed by Stablecoin Development Corporation
- SEC Form 3 filed by new insider Blynn Henry
- Stablecoin Development Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Executive Officer Kazley Michael John exercised 11,332,020 in-the-money shares at a strike of $0.00 and sold $26,945 worth of shares (24,720 units at $1.09) (SEC Form 4)